巨化股份(600160.SH):控股股東首次增持219.2萬股 擬增持5000萬元-10000萬元公司股份
格隆匯4月8日丨巨化股份(600160.SH)公佈,公司於2025年4月8日收到公司控股股東巨化集團有限公司(以下簡稱“巨化集團”)函告,其一致行動人浙江巨化投資有限公司(以下簡稱“巨化投資”)於2025年4月8日通過上海證券交易所證券交易系統增持公司股份219.2萬股,佔公司已發行總股份的0.08%,增持後巨化集團及其一致行動人巨化投資合計持股比例由53.43%增至53.51%。
巨化投資將自本公告日(含本日,下同)起3個月內,增持的金額累計不少於人民幣5000萬元(含本次),不超過人民幣10,000萬元(含本次)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.